Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Tela Bio expects decline in revenue due to COVID, in Q2 suspends FY20 view » 16:21
05/12/20
05/12
16:21
05/12/20
16:21
TELA

Tela Bio

$11.90 /

-0.535 (-4.30%)

Based on the ongoing…

Based on the ongoing impact from restrictions on surgical procedures and shelter-in-place policies, the Company expects revenue to decline in the second quarter of 2020 as compared to the most recent completed quarter and same quarter in 2019. At this time, the full extent of the impact of the COVID-19 pandemic on TELA's business, financial condition and results of operations is uncertain and cannot be predicted with reasonable accuracy. As a result, TELA will continue its suspension of full year 2020 revenue guidance.

ShowHide Related Items >><<
TELA Tela Bio
$11.90 /

-0.535 (-4.30%)

TELA Tela Bio
$11.90 /

-0.535 (-4.30%)

03/27/20 Piper Sandler
Demand for Tela Bio's OviTex/Hernia PRS 'encouraging,' says Piper Sandler
03/03/20 Piper Sandler
Piper recommends three Med Tech names amid coronavirus selloff
01/10/20 Piper Sandler
Tela Bio off to 'encouraging start,' says Piper Sandler
12/18/19 Piper Sandler
Tela Bio shares at 'attractive entry point,' says Piper Jaffray
TELA Tela Bio
$11.90 /

-0.535 (-4.30%)

Earnings
Tela Bio says impacted by pandemic as patients defer elective surgery procedures » 16:20
05/12/20
05/12
16:20
05/12/20
16:20
TELA

Tela Bio

$11.90 /

-0.535 (-4.30%)

TELA's business has…

TELA's business has been impacted by the pandemic as physicians and their patients are required, or are choosing, to defer elective surgery procedures in which TELA's products otherwise would be used. However, TELA is currently employing virtual selling programs and it expects to continue to creatively adapt its sales and marketing plans as it better understands the effects of the COVID-19 pandemic on TELA's business. TELA implemented salary cuts for its employees and initiated actions in April to generate savings in areas such as travel, events, and consulting. TELA continues to work closely with hospital and physician customers and suppliers to navigate through this unforeseen event while maintaining flexible operations.

ShowHide Related Items >><<
TELA Tela Bio
$11.90 /

-0.535 (-4.30%)

TELA Tela Bio
$11.90 /

-0.535 (-4.30%)

03/27/20 Piper Sandler
Demand for Tela Bio's OviTex/Hernia PRS 'encouraging,' says Piper Sandler
03/03/20 Piper Sandler
Piper recommends three Med Tech names amid coronavirus selloff
01/10/20 Piper Sandler
Tela Bio off to 'encouraging start,' says Piper Sandler
12/18/19 Piper Sandler
Tela Bio shares at 'attractive entry point,' says Piper Jaffray
TELA Tela Bio
$11.90 /

-0.535 (-4.30%)

Earnings
Tela Bio reports Q1 EPS (63c), consensus (56c) » 16:19
05/12/20
05/12
16:19
05/12/20
16:19
TELA

Tela Bio

$11.90 /

-0.535 (-4.30%)

Reports Q1 revenue…

Reports Q1 revenue $3.73M, consensus $3.67M.

ShowHide Related Items >><<
TELA Tela Bio
$11.90 /

-0.535 (-4.30%)

TELA Tela Bio
$11.90 /

-0.535 (-4.30%)

03/27/20 Piper Sandler
Demand for Tela Bio's OviTex/Hernia PRS 'encouraging,' says Piper Sandler
03/03/20 Piper Sandler
Piper recommends three Med Tech names amid coronavirus selloff
01/10/20 Piper Sandler
Tela Bio off to 'encouraging start,' says Piper Sandler
12/18/19 Piper Sandler
Tela Bio shares at 'attractive entry point,' says Piper Jaffray
TELA Tela Bio
$11.90 /

-0.535 (-4.30%)

Over a month ago
Conference/Events
Tela Bio management to meet with JMP Securities » 04:55
04/01/20
04/01
04:55
04/01/20
04:55
TELA

Tela Bio

$7.54 /

-0.43 (-5.40%)

Virtual Meeting to be…

Virtual Meeting to be held on April 1 hosted by JMP Securities.

ShowHide Related Items >><<
TELA Tela Bio
$7.54 /

-0.43 (-5.40%)

03/27/20 Piper Sandler
Demand for Tela Bio's OviTex/Hernia PRS 'encouraging,' says Piper Sandler
03/03/20 Piper Sandler
Piper recommends three Med Tech names amid coronavirus selloff
01/10/20 Piper Sandler
Tela Bio off to 'encouraging start,' says Piper Sandler
12/18/19 Piper Sandler
Tela Bio shares at 'attractive entry point,' says Piper Jaffray
Conference/Events
Tela Bio management to meet with JMP Securities » 11:11
03/30/20
03/30
11:11
03/30/20
11:11
TELA

Tela Bio

$8.00 /

-0.05 (-0.62%)

Virtual Meeting to be…

Virtual Meeting to be held on April 1 hosted by JMP Securities.

ShowHide Related Items >><<
TELA Tela Bio
$8.00 /

-0.05 (-0.62%)

03/27/20 Piper Sandler
Demand for Tela Bio's OviTex/Hernia PRS 'encouraging,' says Piper Sandler
03/03/20 Piper Sandler
Piper recommends three Med Tech names amid coronavirus selloff
01/10/20 Piper Sandler
Tela Bio off to 'encouraging start,' says Piper Sandler
12/18/19 Piper Sandler
Tela Bio shares at 'attractive entry point,' says Piper Jaffray
Recommendations
Demand for Tela Bio's OviTex/Hernia PRS 'encouraging,' says Piper Sandler » 13:10
03/27/20
03/27
13:10
03/27/20
13:10
TELA

Tela Bio

$8.60 /

+ (+0.00%)

Piper Sandler analyst…

Piper Sandler analyst Matt O'Brien keeps an Overweight rating and $14 price target on Tela Bio after the company's Q4 results came in at the high-end of its preannounced guidance range. In a research note to investors, O'Brien says the underlying demand for OviTex Hernia/PRS is "encouraging" and that while the short-term may be volatile, he is constructive on the differentiated offering.

ShowHide Related Items >><<
TELA Tela Bio
$8.60 /

+ (+0.00%)

03/03/20 Piper Sandler
Piper recommends three Med Tech names amid coronavirus selloff
01/10/20 Piper Sandler
Tela Bio off to 'encouraging start,' says Piper Sandler
12/18/19 Piper Sandler
Tela Bio shares at 'attractive entry point,' says Piper Jaffray
12/03/19 Jefferies
Jefferies says Tela Bio has 'winning combo,' starts with Buy rating
Earnings
Tela Bio sees Q1 revenue $3.5M-$4M, consensus $5.02M » 07:03
03/27/20
03/27
07:03
03/27/20
07:03
TELA

Tela Bio

$8.60 /

+0.8 (+10.26%)

For the first quarter of…

For the first quarter of 2020, TELA Bio expects total revenue to be in the range of $3.5 million to $4.0 million, representing growth of 6% to 21% over the prior year period. Due to uncertainties in procedural volume stemming from COVID-19 and its potential negative impact on its financials, TELA Bio is not providing guidance for the full year 2020. The Company intends to provide an update during its first quarter 2020 earnings call.

ShowHide Related Items >><<
TELA Tela Bio
$8.60 /

+0.8 (+10.26%)

03/03/20 Piper Sandler
Piper recommends three Med Tech names amid coronavirus selloff
01/10/20 Piper Sandler
Tela Bio off to 'encouraging start,' says Piper Sandler
12/18/19 Piper Sandler
Tela Bio shares at 'attractive entry point,' says Piper Jaffray
12/03/19 Jefferies
Jefferies says Tela Bio has 'winning combo,' starts with Buy rating
Earnings
Tela Bio reports Q4 EPS ($1.22), consensus (59c) » 07:02
03/27/20
03/27
07:02
03/27/20
07:02
TELA

Tela Bio

$8.60 /

+0.8 (+10.26%)

Reports Q4 revenue $4.9M,…

Reports Q4 revenue $4.9M, consensus $4.18M. "2019 was a year of many accomplishments, including significant revenue growth driven by the adoption of our OviTex and OviTex PRS product lines, expansion of our commercial organization, the signing of a major group purchasing agreement, publication of compelling clinical data, and the completion of a successful IPO," said Antony Koblish, co-founder, President and Chief Executive Officer of TELA Bio. "As we look towards 2020, we share in a collective concern for the impact of the COVID-19 pandemic across the globe. While it is too early and uncertain to determine the actual effects of this pandemic on our business, we are beginning to feel the impact and intend to use many of our business levers to best position our Company for the long-term, leveraging our strong clinical data, sales, marketing and GPO strategies."

ShowHide Related Items >><<
TELA Tela Bio
$8.60 /

+0.8 (+10.26%)

03/03/20 Piper Sandler
Piper recommends three Med Tech names amid coronavirus selloff
01/10/20 Piper Sandler
Tela Bio off to 'encouraging start,' says Piper Sandler
12/18/19 Piper Sandler
Tela Bio shares at 'attractive entry point,' says Piper Jaffray
12/03/19 Jefferies
Jefferies says Tela Bio has 'winning combo,' starts with Buy rating
Over a quarter ago
Recommendations
Piper recommends three Med Tech names amid coronavirus selloff » 06:30
03/03/20
03/03
06:30
03/03/20
06:30
BSX

Boston Scientific

$38.23 /

+0.34 (+0.90%)

, ALGN

Align Technology

$230.32 /

+5.7 (+2.54%)

, MMSI

Merit Medical

$36.89 /

+0.44 (+1.21%)

, DXCM

DexCom

$286.00 /

+4.73 (+1.68%)

, GMED

Globus Medical

$47.09 /

-0.215 (-0.45%)

, TELA

Tela Bio

$15.24 /

-1.16 (-7.07%)

Stocks across Medical…

Stocks across Medical Technology and Devices have pulled back due to fears over the coronavirus, with multiples back in-line with three-year averages, Piper Sandler analyst Matt O'Brien tells investors in a research note. In the analyst's coverage, Align Technology (ALGN) and Merit Medical (MMSI) have the most revenue exposure to China, with DexCom (DXCM) and Globus Medical (GMED) among the least exposed large and mid cap names, respectively. The names O'Brien would own, specifically related to the impact of coronavirus on their stock price, are Boston Scientific (BSX), Globus Medical and Tela Bio (TELA) in large, mid-, and small-cap med tech.

ShowHide Related Items >><<
BSX Boston Scientific
$38.23 /

+0.34 (+0.90%)

02/12/20 Goldman Sachs
Boston Scientific initiated with a Neutral at Goldman Sachs
02/05/20 Piper Sandler
Piper Sandler constructive on Boston Scientific given guidance, new product flow
01/17/20 Piper Sandler
FDA recommendation a 'solid tailwind' for Boston Scientific, says Piper Sandler
01/15/20 Cowen
Boston Scientific weakness a buying opportunity, says Cowen
ALGN Align Technology
$230.32 /

+5.7 (+2.54%)

01/31/20 Benchmark
Too early to call China emergency impact on Staar Surgical, says Benchmark
01/30/20 Piper Sandler
Align Technology price target raised to $275 from $240 at Piper Sandler
01/15/20 Jefferies
SmileDirect traditional channel entry makes competitive 'noise,' says Jefferies
01/09/20 Wolfe Research
Align Technology upgraded to Outperform from Peer Perform at Wolfe Research
MMSI Merit Medical
$36.89 /

+0.44 (+1.21%)

02/25/20 Barrington
Barrington downgrades Merit Medical to Market Perform on coronavirus risk
02/25/20 Barrington
Merit Medical downgraded to Market Perform from Outperform at Barrington
02/25/20 Wells Fargo
Merit Medical price target raised to $33 from $26 at Wells Fargo
02/25/20 Raymond James
Merit Medical price target raised to $47 from $43 at Raymond James
DXCM DexCom
$286.00 /

+4.73 (+1.68%)

02/19/20 Piper Sandler
New partnerships expected, but positive, for Insulet, says Piper Sandler
02/14/20 Raymond James
DexCom price target raised to $288 from $258 at Raymond James
02/14/20 Oppenheimer
DexCom price target raised to $285 from $250 at Oppenheimer
02/14/20 Cowen
DexCom price target raised to $300 from $250 at Cowen
GMED Globus Medical
$47.09 /

-0.215 (-0.45%)

01/10/20 Cantor Fitzgerald
Cantor still bullish on Medical Devices & Suppliers heading into 2020
01/09/20 SVB Leerink
Globus Medical guidance looks conservative, says SVB Leerink
01/09/20 Canaccord
Globus Medical guidance looks conservative not weak, says Canaccord
01/09/20 Cantor Fitzgerald
Globus Medical guidance for 2020 looks conservative, says Cantor Fitzgerald
TELA Tela Bio
$15.24 /

-1.16 (-7.07%)

01/10/20 Piper Sandler
Tela Bio off to 'encouraging start,' says Piper Sandler
12/18/19 Piper Sandler
Tela Bio shares at 'attractive entry point,' says Piper Jaffray
12/03/19 Jefferies
Jefferies says Tela Bio has 'winning combo,' starts with Buy rating
12/03/19 Jefferies
Tela Bio initiated with a Buy at Jefferies
Hot Stocks
Tela Bio announces data on biologic material used in a hernia repair published » 16:21
02/04/20
02/04
16:21
02/04/20
16:21
TELA

Tela Bio

$15.39 /

+0.19 (+1.25%)

Tela Bio announced data…

Tela Bio announced data from a non-human primate study demonstrating favorable response to reinforced biologic material used in a hernia repair compared to seven clinically used biologic and synthetic products. The data are published online in the journal, Hernia, the world journal of hernia and abdominal wall surgery. Hernia is published in cooperation with the American Hernia Society, the European Hernia Society, the Americas Hernia Society, and the Asia Pacific Hernia Society. The study is the first of its kind to compare a wide variety of commercially used biologic, reinforced biologic and synthetic hernia repair materials in an animal model to predict clinical performance. The study used adult non-human primates, a species that shares greater than 98% of its DNA with humans and thus provides the best possible model to predict the response of the human immune system and healing kinetics. In the study, two reinforced biologics, OviTex 1S Resorbable and OviTex 1S Permanent, were studied in a non-human primate hernia repair model and were evaluated for their biologic performance as measured by inflammatory response, healing kinetics, integration, and remodeling into functional host tissue. For comparison, seven clinically used biologic and synthetic meshes were also studied. Seventy-three non-human primates were implanted with test articles in surgically created full thickness midline abdominal wall defects. Clinical observations were recorded daily. Implants were recovered at 4, 12, and 24 weeks and evaluated for signs of herniation, inflammation, adhesions, contraction, or other abnormalities as well as evidence of healing and integration. The results showed that both the reinforced biologics and biologics remodeled into naturally appearing tissue and were associated with low levels of inflammation. However, reinforced biologics showed earlier cellular and blood vessel infiltration than biologics. This resulted in earlier remodeling and better maintenance of the geometry of the repair. In contrast, a foreign body response persisted with the synthetic mesh products which manifested itself as a layer of reactive tissue often above and separate from the contracted mesh structure.

ShowHide Related Items >><<
TELA Tela Bio
$15.39 /

+0.19 (+1.25%)

01/10/20 Piper Sandler
Tela Bio off to 'encouraging start,' says Piper Sandler
12/18/19 Piper Sandler
Tela Bio shares at 'attractive entry point,' says Piper Jaffray
12/03/19 Jefferies
Jefferies says Tela Bio has 'winning combo,' starts with Buy rating
12/03/19 Jefferies
Tela Bio initiated with a Buy at Jefferies

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.